FYERS
Genpharmasec1.15
+0.01 (+0.88%)

Genpharmasec Share Price

1.15+0.01 (+0.88%)
-44.17% past 1 Year

Corporate filings & documents

Announcements

Newspaper Publication of Notice of AGM to be held on 29th September 2026.
1 week ago
Newspaper Publication of Notice of AGM to be held on 29th September 2026.
1 week ago
Annual Report for Financial Year 2025-26.
2 weeks ago
Annual Report for Financial Year 2025-26.
2 weeks ago
Notice of 34th Annual General Meeting of the company to be held on September 29 2026.
2 weeks ago
Notice of 34th Annual General Meeting of the company to be held on September 29 2026.
2 weeks ago
Intimation of Book Closure for AGM to be held on 29th September 2026.
2 weeks ago
Intimation of Book Closure for AGM to be held on 29th September 2026.
2 weeks ago
Outcome of the Meeting of Board of Directors held on Wednesday 02nd September 2026.
2 weeks ago
Outcome of the Meeting of Board of Directors held on Wednesday 02nd September 2026.
2 weeks ago
Outcome of the Meeting of Board of Directors held on Wednesday 02nd September 2026.
2 weeks ago
Outcome of the Meeting of Board of Directors held on Wednesday 02nd September 2026.
2 weeks ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Sadhwani & PACs
2 weeks ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Sadhwani & PACs
2 weeks ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Sadhwani
3 weeks ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Sadhwani
3 weeks ago
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 inter alia to consider and approve 1. To Fix the Day Date Time and Mode of 34th Annual General Meeting of the Company for the year ended March 31 2026 and approve Draft notice and Calendar of Events for the same. 2. To Fix the Cut- off date to determine the entitlement of voting rights of members for E-voting and to fix the commencement and closing date for E-voting. 3. To consider and approve the Directors Report for the year ended March 31 2026. 4. To consider and approve Annual Report for Financial Year 2025-26. 5. To approve closure of Share Transfer Books & Register of Members for the 34th Annual General Meeting. 6. To Consider and approve the appointment of Scrutinizer for E-voting at the ensuing 34th Annual General Meeting. 7. Any other Matter with the permission of the Chairman.
3 weeks ago
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 inter alia to consider and approve 1. To Fix the Day Date Time and Mode of 34th Annual General Meeting of the Company for the year ended March 31 2026 and approve Draft notice and Calendar of Events for the same. 2. To Fix the Cut- off date to determine the entitlement of voting rights of members for E-voting and to fix the commencement and closing date for E-voting. 3. To consider and approve the Directors Report for the year ended March 31 2026. 4. To consider and approve Annual Report for Financial Year 2025-26. 5. To approve closure of Share Transfer Books & Register of Members for the 34th Annual General Meeting. 6. To Consider and approve the appointment of Scrutinizer for E-voting at the ensuing 34th Annual General Meeting. 7. Any other Matter with the permission of the Chairman.
3 weeks ago
Regarding Recent Agreement with Amneal Healthcare Private Limited
1 month ago
Regarding Recent Agreement with Amneal Healthcare Private Limited
1 month ago
Newspaper Publication of Unaudited Financial Results for the quarter ended 30th June 2026.
1 month ago
Newspaper Publication of Unaudited Financial Results for the quarter ended 30th June 2026.
1 month ago
Statement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th June 2026.
1 month ago
Statement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th June 2026.
1 month ago
Unaudited Standalone & Consolidated Financial Results of the company for the quarter ended 30th June 2026.
1 month ago
Unaudited Standalone & Consolidated Financial Results of the company for the quarter ended 30th June 2026.
1 month ago
Outcome of the Meeting of Board of Directors held on Tuesday 11th August 2026.
1 month ago
Outcome of the Meeting of Board of Directors held on Tuesday 11th August 2026.
1 month ago
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve 1. To consider and approve Un-audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the quarter ended 30th June 2026. 2. To consider any other business with the permission of a Chairman.
1 month ago
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve 1. To consider and approve Un-audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the quarter ended 30th June 2026. 2. To consider any other business with the permission of a Chairman.
1 month ago
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended June 30 2026.
2 months ago
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended June 30 2026.
2 months ago
Intimation of Closure of Trading Window
2 months ago
Intimation of Closure of Trading Window
2 months ago
Annual Secretarial Compliance Report for the year ended March 31 2026.
3 months ago
Annual Secretarial Compliance Report for the year ended March 31 2026.
3 months ago
Newspaper Publication of Audited Financial Result for the quarter and year ended 31st March 2026.
4 months ago
Newspaper Publication of Audited Financial Result for the quarter and year ended 31st March 2026.
4 months ago
Statement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st March 2026.
4 months ago
Statement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st March 2026.
4 months ago
Audited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March 2026.
4 months ago
Audited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March 2026.
4 months ago
Outcome of the Meeting of Board of Directors held on Thursday May 21 2026.
4 months ago
Outcome of the Meeting of Board of Directors held on Thursday May 21 2026.
4 months ago
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve 1. To consider approve & take on record the Audited Standalone and Consolidated Financial Results of the Company along with the Auditors Report thereon for the Quarter and Year ended 31st March 2026.2. To consider any other business with the permission of a Chairman of the Meeting.
4 months ago
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve 1. To consider approve & take on record the Audited Standalone and Consolidated Financial Results of the Company along with the Auditors Report thereon for the Quarter and Year ended 31st March 2026.2. To consider any other business with the permission of a Chairman of the Meeting.
4 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Genpharmasec Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24231MH1992PLC323914</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Hardik Makwana <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Mr Sohan Chaturvedi <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 14/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Genpharmasec Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24231MH1992PLC323914</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Hardik Makwana <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Mr Sohan Chaturvedi <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 14/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months ago
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended March 31 2026.
5 months ago
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended March 31 2026.
5 months ago

Annual reports

FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21

Concalls & investor presentations

Empty box

No presentations found

Genpharmasec Ltd Share Price Today

The Genpharmasec Ltd share price today is ₹1.17. During the trading session, the Genpharmasec Ltd share price opened at ₹1.23 and recorded an intraday high of ₹1.25 and a low of ₹1.15. Last closing price was ₹1.25. Over the past 52 weeks, the Genpharmasec Ltd share price has ranged between ₹0.75 and ₹2.15. The current Genpharmasec Ltd stock price reflects real-time market activity based on executed trades on the exchange.